MRNA- Leader in the vaccine race. Ladder buy to avoid the risk

Moderna is the first company to start the phase 3 trial in July and could have the supply ready earliest by Oct and accelerated approval earliest by December, according to Nami Sumida/BioPharma Dive and morningstar.

Other competitors are scheduled to have accelerated approval the earliest around early 2021.